BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21220520)

  • 1. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.
    Yi JH; Kim JH; Baek KK; Lim T; Lee DJ; Ahn YC; Kim K; Kim SJ; Ko YH; Kim WS
    Ann Oncol; 2011 Jul; 22(7):1636-1643. PubMed ID: 21220520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
    Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.
    Ellin F; Landström J; Jerkeman M; Relander T
    Blood; 2015 Jul; 126(1):36-41. PubMed ID: 25957393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
    Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
    Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
    Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
    Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system involvement in diffuse large B-cell lymphoma.
    Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
    Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
    Qin Y; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Liu XF; Liu P; Yang S; Zhou LQ; Han XH; Yao JR
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):448-51. PubMed ID: 20819488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system involvement in T-cell lymphoma: A single center experience.
    Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
    Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].
    Yang H; Lang RG; Liu FF; Wang XF; Jin ZJ; Lü AJ; Wang Y; Fu XL; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):79-84. PubMed ID: 21426801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
    Kim SJ; Oh SY; Hong JY; Chang MH; Lee DH; Huh J; Ko YH; Ahn YC; Kim HJ; Suh C; Kim K; Kim WS
    Ann Oncol; 2010 May; 21(5):1058-63. PubMed ID: 19850636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas.
    Kaito S; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y; Hishima T; Maeda Y
    Int J Hematol; 2018 Apr; 107(4):451-459. PubMed ID: 29103138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J; Chen B; Xu X
    Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases].
    Su ZY; Zhang DS; Zhu MQ; Shi YX; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):919-22. PubMed ID: 17697560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy.
    El-Sharkawi D; Basu S; Ocampo C; Qian W; D'Sa S; Hoskin PJ; Ardeshna KM
    Leuk Lymphoma; 2012 Oct; 53(10):1949-52. PubMed ID: 22462615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
    Liang X; Guo L; Hu X; Li S; Wen S
    Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
    Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
    Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
    Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
    Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
    Oka S; Ono K; Nohgawa M
    Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.